Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.
BACKGROUND: Statin treatment improves survival in patients with atherosclerosis, but their effect on the glucose-induced variations of inflammatory markers, is unknown. We examined the effect of combined therapy with atorvastatin and metformin on glucose-induced variations of inflammatory molecules...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826271552902004736 |
|---|---|
| author | Tousoulis, D Koniari, K Antoniades, C Papageorgiou, N Miliou, A Noutsou, M Nikolopoulou, A Marinou, K Stefanadi, E Siasos, G Charakida, M Kamboli, A Stefanadis, C |
| author_facet | Tousoulis, D Koniari, K Antoniades, C Papageorgiou, N Miliou, A Noutsou, M Nikolopoulou, A Marinou, K Stefanadi, E Siasos, G Charakida, M Kamboli, A Stefanadis, C |
| author_sort | Tousoulis, D |
| collection | OXFORD |
| description | BACKGROUND: Statin treatment improves survival in patients with atherosclerosis, but their effect on the glucose-induced variations of inflammatory markers, is unknown. We examined the effect of combined therapy with atorvastatin and metformin on glucose-induced variations of inflammatory molecules in patients with newly diagnosed diabetes mellitus type 2 (DM). METHODS: Thirty five subjects with newly diagnosed DM were randomized to receive metformin 850 mg/d (M, n=17) or metformin 850 mg/d+atorvastatin 10mg (n=18). All subjects underwent glucose loading (75 g oral glucose) at baseline and after 12 weeks of treatment. Blood samples were obtained at baseline and 3h post-loading, while serum tumor necrosis factor alpha (TNF-α) levels were determined at baseline and at 3h. RESULTS: Serum TNF-α remained unchanged in metformin at baseline (1.36±0.18 to 1.47±0.21 pg/ml p=NS) and after treatment (1.44±0.71 to 1.31±0.17 pg/ml, p=NS), while it was reduced in metformin+atorvastatin (2.3±0.3 to 2.0±0.4 pg/ml, p=NS at baseline and 1.80±0.2 to 1.65±0.2 pg/ml, p=0.03 after treatment). CONCLUSIONS: Interestingly, the combination of metformin and atorvastatin partly prevents the glucose-loading induced elevation of glucose levels (at 1 h), suggesting a better response to glucose intake than monotherapy with metformin. In addition, combined treatment with atorvastatin and metformin reduces the post-glucose loading levels of TNF-α compared to metformin monotherapy. |
| first_indexed | 2024-03-06T21:58:28Z |
| format | Journal article |
| id | oxford-uuid:4dc3b02d-bf0e-4983-9f24-ad5193a78c04 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:58:28Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:4dc3b02d-bf0e-4983-9f24-ad5193a78c042022-03-26T15:57:25ZCombined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4dc3b02d-bf0e-4983-9f24-ad5193a78c04EnglishSymplectic Elements at Oxford2011Tousoulis, DKoniari, KAntoniades, CPapageorgiou, NMiliou, ANoutsou, MNikolopoulou, AMarinou, KStefanadi, ESiasos, GCharakida, MKamboli, AStefanadis, C BACKGROUND: Statin treatment improves survival in patients with atherosclerosis, but their effect on the glucose-induced variations of inflammatory markers, is unknown. We examined the effect of combined therapy with atorvastatin and metformin on glucose-induced variations of inflammatory molecules in patients with newly diagnosed diabetes mellitus type 2 (DM). METHODS: Thirty five subjects with newly diagnosed DM were randomized to receive metformin 850 mg/d (M, n=17) or metformin 850 mg/d+atorvastatin 10mg (n=18). All subjects underwent glucose loading (75 g oral glucose) at baseline and after 12 weeks of treatment. Blood samples were obtained at baseline and 3h post-loading, while serum tumor necrosis factor alpha (TNF-α) levels were determined at baseline and at 3h. RESULTS: Serum TNF-α remained unchanged in metformin at baseline (1.36±0.18 to 1.47±0.21 pg/ml p=NS) and after treatment (1.44±0.71 to 1.31±0.17 pg/ml, p=NS), while it was reduced in metformin+atorvastatin (2.3±0.3 to 2.0±0.4 pg/ml, p=NS at baseline and 1.80±0.2 to 1.65±0.2 pg/ml, p=0.03 after treatment). CONCLUSIONS: Interestingly, the combination of metformin and atorvastatin partly prevents the glucose-loading induced elevation of glucose levels (at 1 h), suggesting a better response to glucose intake than monotherapy with metformin. In addition, combined treatment with atorvastatin and metformin reduces the post-glucose loading levels of TNF-α compared to metformin monotherapy. |
| spellingShingle | Tousoulis, D Koniari, K Antoniades, C Papageorgiou, N Miliou, A Noutsou, M Nikolopoulou, A Marinou, K Stefanadi, E Siasos, G Charakida, M Kamboli, A Stefanadis, C Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. |
| title | Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. |
| title_full | Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. |
| title_fullStr | Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. |
| title_full_unstemmed | Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. |
| title_short | Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. |
| title_sort | combined effects of atorvastatin and metformin on glucose induced variations of inflammatory process in patients with diabetes mellitus |
| work_keys_str_mv | AT tousoulisd combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT koniarik combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT antoniadesc combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT papageorgioun combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT milioua combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT noutsoum combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT nikolopouloua combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT marinouk combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT stefanadie combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT siasosg combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT charakidam combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT kambolia combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus AT stefanadisc combinedeffectsofatorvastatinandmetforminonglucoseinducedvariationsofinflammatoryprocessinpatientswithdiabetesmellitus |